Geriatric Assessment (GA) for Elderly Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Prospective Study.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 176
- 试验地点
- 2
- 主要终点
- Transplant-related mortality
研究概览
简要总结
This comprehensive, multidimensional evaluation assesses patient-related factors, disease-related factors, donor-related factors, and treatment-related factors. The study aims to identify potential risk factors influencing transplant outcomes in elderly patients and enhance the outcomes of allo-HSCT.
详细描述
This comprehensive, multidimensional evaluation assesses patient-related factors (e.g., age, physical function, and comorbidity index), disease-related factors (e.g., primary diagnosis and blast count), donor-related factors (e.g., donor age, sex, ABO, and type), and treatment-related factors (e.g., conditioning regimen, graft source, and GVHD prophylaxis). The study aims to identify potential risk factors influencing transplant outcomes in elderly patients, establish a comprehensive geriatric assessment model, and guide personalized pre-transplant treatment strategies to reduce transplant-related mortality (TRM). Ultimately, we hope this study could help enhance the outcomes of allogenic hematopoietic stem cell transplantation (allo-HSCT).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(a)Age ≥55 years.
- •(b)Hematologic disorders with established indications for transplantation, including malignant and non-malignant hematologic diseases. (c)Willingness to provide informed consent.
排除标准
- •(a)Pregnancy. (b) Uncontrolled active infection. (c) Lack of informed consent. (d)Deemed ineligible for transplantation after investigator assessment
研究组 & 干预措施
Geriatric Assessment
干预措施: Geriatric Assessment (Procedure)
结局指标
主要结局
Transplant-related mortality
时间窗: From HSCT to the follow-up assessment at 12 months post-treatment.
Transplant-related mortality (TRM) is defined as death due to any transplantation-related cause other than disease relapse. Transplant-related mortality will be calculated using a competing risks model.
次要结局
- Engraftment(From HSCT to the follow-up assessment at 12 months post-treatment.)
- GVHD(From HSCT to the follow-up assessment at 12 months post-treatment.)
- Overall Survival(From HSCT to the follow-up assessment at 12 months post-treatment.)
- Cumulative Incidence of Relapse(From HSCT to the follow-up assessment at 12 months post-treatment.)
- Disease-Free Survival(From HSCT to the follow-up assessment at 12 months post-treatment.)
- Viral Infection(From HSCT to the follow-up assessment at 12 months post-treatment.)
研究者
Sun Yuqian
Associate Professor
Peking University People's Hospital